Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

January 23, 2013 updated by: Daewon Pharmaceutical Co., Ltd.

A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

A randomized, open-labeled, comparative 3-way crossover study to compare the pharmacokinetic characteristics and food effect of pelubiprofen (30mg) tablet IR TID and pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD in healthy subjects.

Study Overview

Status

Completed

Conditions

Healthy

Intervention / Treatment

Study Type

Interventional

Phase

Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 45 years (Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

Male

Description

Inclusion Criteria:

Adult Healthy males aged 20~45 years
weight over 45 kg, ideal body weight ±20%[Ideal weight] = [Height(cm)-100] X 0.9
Subjects who voluntarily agreed with written consent

Exclusion Criteria:

Patients with acute disorder within 28 days before clinical trial drugs administration
History of disorders(inflammatory GI tract disease, stomach ulcer, gastrectomy, liver disease) which can affect ADME of drugs
Patients with active GI tract, cardiovascular, respiratory, renal, endocrinal, haematological, central nerval, psychiatric disease or malignant tumor

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: pelubiprofen (30mg) tablet IR TID, fasting	Drug: pelubiprofen (30mg) tablet IR
Active Comparator: pelubiprofen (30mg) tablet IR TID, fed	Drug: pelubiprofen (30mg) tablet IR
Experimental: pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD	Drug: pelubiprofen SR (as a pelubiprofen 90 mg) tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
AUC of pelubiprofen(30mg) tablet IR TID Time Frame: 0, 1, 2, 8, 9, 15, 16, 22 day	0, 1, 2, 8, 9, 15, 16, 22 day
AUC of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD Time Frame: 0, 1, 2, 8, 9, 15, 16, 22 day	0, 1, 2, 8, 9, 15, 16, 22 day
Cmax of pelubiprofen(30mg) tablet IR TID Time Frame: 0, 1, 2, 8, 9, 15, 16, 22 day	0, 1, 2, 8, 9, 15, 16, 22 day
Cmax of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD Time Frame: 0, 1, 2, 8, 9, 15, 16, 22 day	0, 1, 2, 8, 9, 15, 16, 22 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Daewon Pharmaceutical Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

April 1, 2012

Study Completion (Actual)

April 1, 2012

Study Registration Dates

First Submitted

January 22, 2013

First Submitted That Met QC Criteria

January 23, 2013

First Posted (Estimate)

January 28, 2013

Study Record Updates

Last Update Posted (Estimate)

January 28, 2013

Last Update Submitted That Met QC Criteria

January 23, 2013

Last Verified

January 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

DW330SR-1001(Ver2.2)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

University of Vermont Medical Center
Avocado Nutrition Center

Recruiting

Avocado and Postprandial Responses

Healthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokers

United States
Dragonfly Therapeutics

Recruiting

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults (DF5112)

Healthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult Male

Australia
University of Palermo

Completed

Neck Static Stretching Acutely Reduces Blood Pressure Through Reduction of Tissue Stiffness

Healthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | Stretching

Italy
Prevent Age Resort "Pervaya Liniya"

Recruiting

First Line Prevent Age Study (FLIPS)

Healthy Aging | Healthy Diet | Healthy Lifestyle

Russian Federation
Yale University

Not yet recruiting

Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health

Healthy Diet | Healthy Lifestyle | Healthy Nutrition | Cholesterol

United States
Umm Al-Qura University

Active, not recruiting

Effect of Magnesium Supplementation on Sleep Quality and Cognitive Function in Saudi Adults

Healthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult Subjects

Saudi Arabia
University of Palermo

Completed

Roller Massage and Blood Pressure

Healthy Participants | Healthy Adult Participants | Healthy Young Adults

Italy
Maastricht University Medical Center

Completed

Reference Gait Data for Healthy Subjects

Healthy Volunteers | Healthy Subjects | Healthy Adults

Netherlands
Pfizer

Not yet recruiting

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

Healthy | Healthy Adults

United States
RAGE Bio

Recruiting

Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers

Healthy | Healthy Smoker

Australia

Clinical Trials on pelubiprofen (30mg) tablet IR

Daewon Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects

Healthy Males
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
Haiphong University of Medicine and Pharmacy
Daewon Pharmaceutical Co., Ltd.; Big Leap Research

Recruiting

Comparison of DW-1021 and Separate Doses of Pelubi CR and Zytram CR Under Fasting Conditions (DW-1021)

Healthy Volunteer

Vietnam
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy
Stallergenes Greer

Completed

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Allergy
Stallergenes Greer

Completed

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Primary Disease

France, Italy, Spain
Stallergenes Greer

Completed

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Allergic Rhinitis Due to Grass Pollens

United States
Stallergenes Greer

Completed

Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Allergic Rhinitis Due to House Dust Mite

Canada
GlaxoSmithKline

Completed

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

Cancer

Australia
Stallergenes Greer

Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Allergy

Germany

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Phase

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Other Study ID Numbers

Clinical Trials on Healthy

Clinical Trials on pelubiprofen (30mg) tablet IR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations